What factors led to IVD companies no longer developing immunoassays in-house?
To clarify, years ago, most of the clinical validation was completed in-house using frozen samples. Now, many IVD companies perform validation externally. As far as discovery, the challenge becomes one of focus and cost. We prefer to focus our basic research on a couple of areas. To do the process justice, developers have to dive deep. Manufacturers have to choose specific areas to concentrate their research, because it is prohibitively expensive to cover the whole field. So reaching out to academicians provides more extended opportunities. I think it is beneficial for the academicians as well because industry collaborations provide sources of funding other than just government grants. National Institutes of Health funding has decreased over the years, and diagnostic companies provide additional sources of funding for academic research. Overall, it is a mutually beneficial relationship. What factors must IVD manufacturers consider when developing assays that are used on their instrumen
Related Questions
- Are there free web-based resources for researching historical stock prices of companies that no longer trade publicly?
- What are the more challenging areas companies have to address in terms of manufacturing IVD products in-house?
- What are the factors that companies should consider while developing their outsourcing strategy?
